Perceptive Advisors LLC boosted its stake in VBI Vaccines, Inc. – (NASDAQ:VBIV) by 47.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,665,843 shares of the biopharmaceutical company’s stock after purchasing an additional 3,100,000 shares during the period. VBI Vaccines comprises about 1.4% of Perceptive Advisors LLC’s holdings, making the stock its 17th largest holding. Perceptive Advisors LLC owned about 15.15% of VBI Vaccines worth $41,273,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently modified their holdings of VBIV. BVF Inc. IL bought a new position in VBI Vaccines in the 4th quarter valued at approximately $13,237,000. Harel Insurance Investments & Financial Services Ltd. bought a new position in VBI Vaccines in the 4th quarter valued at approximately $7,000,000. Sphera Funds Management LTD. bought a new position in VBI Vaccines in the 4th quarter valued at approximately $3,416,000. General American Investors Co. Inc. bought a new position in VBI Vaccines in the 4th quarter valued at approximately $2,562,000. Finally, BlackRock Inc. lifted its stake in VBI Vaccines by 63.7% in the 4th quarter. BlackRock Inc. now owns 1,509,286 shares of the biopharmaceutical company’s stock valued at $6,445,000 after purchasing an additional 587,036 shares during the last quarter. 48.64% of the stock is owned by institutional investors and hedge funds.
VBI Vaccines, Inc. – (NASDAQ:VBIV) opened at $4.06 on Monday. VBI Vaccines, Inc. – has a 52 week low of $3.04 and a 52 week high of $6.60. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.26 and a current ratio of 5.32.
In other VBI Vaccines news, CEO Jeff Baxter purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The stock was purchased at an average price of $3.89 per share, with a total value of $38,900.00. Following the completion of the purchase, the chief executive officer now owns 140,646 shares of the company’s stock, valued at $547,112.94. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 34.10% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Perceptive Advisors LLC Has $41.27 Million Position in VBI Vaccines, Inc. – (VBIV)” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/03/12/perceptive-advisors-llc-has-41-27-million-position-in-vbi-vaccines-inc-vbiv.html.
VBI Vaccines Company Profile
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Want to see what other hedge funds are holding VBIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VBI Vaccines, Inc. – (NASDAQ:VBIV).
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.